Abstract
Background: We performed an updated meta-Analysis of randomized controlled trials of combination therapy with cholinesterase inhibitors and memantine in patients with Alzheimer's disease. Methods: We reviewed cognitive function, activities of daily living, behavioral disturbance, global assessment, discontinuation rate, and individual side effects. Results: Seven studies (total n = 2182) were identified. Combination therapy significantly affected behavioral disturbance scores (standardized mean difference = 0.13), activity of daily living scores (standardized mean difference = 0.10), and global assessment scores (standardized mean difference = 0.15). In addition, cognitive function scores (standardized mean difference = 0.13, P = .06) exhibited favorable trends with combination therapy. The effects of combination therapy were more significant in the moderate-to-severe Alzheimer's disease subgroup in terms of all efficacy outcome scores. The discontinuation rate was similar in both groups, and there were no significant differences in individual side effects. Conclusions: Combination therapy was beneficial for the treatment of moderate-to-severe Alzheimer's disease in terms of cognition, behavioral disturbances, activities of daily living, and global assessment was well tolerated..
| Original language | English |
|---|---|
| Pages (from-to) | 1-11 |
| Number of pages | 11 |
| Journal | International Journal of Neuropsychopharmacology |
| Volume | 18 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - 01-03-2015 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Pharmacology
- Psychiatry and Mental health
- Pharmacology (medical)
Cite this
}
Combination therapy with cholinesterase inhibitors and memantine for alzheimer's disease : A systematic review and meta-Analysis. / Matsunaga, Shinji; Kishi, Taro; Iwata, Nakao.
In: International Journal of Neuropsychopharmacology, Vol. 18, No. 5, 01.03.2015, p. 1-11.Research output: Contribution to journal › Article
TY - JOUR
T1 - Combination therapy with cholinesterase inhibitors and memantine for alzheimer's disease
T2 - A systematic review and meta-Analysis
AU - Matsunaga, Shinji
AU - Kishi, Taro
AU - Iwata, Nakao
PY - 2015/3/1
Y1 - 2015/3/1
N2 - Background: We performed an updated meta-Analysis of randomized controlled trials of combination therapy with cholinesterase inhibitors and memantine in patients with Alzheimer's disease. Methods: We reviewed cognitive function, activities of daily living, behavioral disturbance, global assessment, discontinuation rate, and individual side effects. Results: Seven studies (total n = 2182) were identified. Combination therapy significantly affected behavioral disturbance scores (standardized mean difference = 0.13), activity of daily living scores (standardized mean difference = 0.10), and global assessment scores (standardized mean difference = 0.15). In addition, cognitive function scores (standardized mean difference = 0.13, P = .06) exhibited favorable trends with combination therapy. The effects of combination therapy were more significant in the moderate-to-severe Alzheimer's disease subgroup in terms of all efficacy outcome scores. The discontinuation rate was similar in both groups, and there were no significant differences in individual side effects. Conclusions: Combination therapy was beneficial for the treatment of moderate-to-severe Alzheimer's disease in terms of cognition, behavioral disturbances, activities of daily living, and global assessment was well tolerated..
AB - Background: We performed an updated meta-Analysis of randomized controlled trials of combination therapy with cholinesterase inhibitors and memantine in patients with Alzheimer's disease. Methods: We reviewed cognitive function, activities of daily living, behavioral disturbance, global assessment, discontinuation rate, and individual side effects. Results: Seven studies (total n = 2182) were identified. Combination therapy significantly affected behavioral disturbance scores (standardized mean difference = 0.13), activity of daily living scores (standardized mean difference = 0.10), and global assessment scores (standardized mean difference = 0.15). In addition, cognitive function scores (standardized mean difference = 0.13, P = .06) exhibited favorable trends with combination therapy. The effects of combination therapy were more significant in the moderate-to-severe Alzheimer's disease subgroup in terms of all efficacy outcome scores. The discontinuation rate was similar in both groups, and there were no significant differences in individual side effects. Conclusions: Combination therapy was beneficial for the treatment of moderate-to-severe Alzheimer's disease in terms of cognition, behavioral disturbances, activities of daily living, and global assessment was well tolerated..
UR - http://www.scopus.com/inward/record.url?scp=84931266099&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84931266099&partnerID=8YFLogxK
U2 - 10.1093/ijnp/pyu115
DO - 10.1093/ijnp/pyu115
M3 - Article
C2 - 25548104
AN - SCOPUS:84931266099
VL - 18
SP - 1
EP - 11
JO - International Journal of Neuropsychopharmacology
JF - International Journal of Neuropsychopharmacology
SN - 1461-1457
IS - 5
ER -